Latest News
P4 Diagnostix Acquires Strand Diagnostics to Enhance Diagnostics Testing Offerings
Thursday 13 February 2020

13 February 2020 - US diagnostic testing laboratory network P4 Diagnostix has acquired the assets of Strand Diagnostics, creator of the know error system in an agreement that re-establishes DNA confirmation testing and solidifies supply chain aspects for urology group practices, the company said.
Terms of the transaction were not disclosed.
Strand's suite of DNA Specimen Provenance Testing is in the field of DNA confirmation testing.
In addition to forensic DNA know error system, the company offers UroSeq germline testing that can be used in accordance with NCCN guidelines for patients with advanced prostate cancer.
P4 plans to re-energise the brand and immediately resume testing, supplies and logistics for all know error clients.
The acquisition will offer P4 Diagnostix clients a wider range of offerings and services for diagnostic testing needs.
P4 Diagnostix is a network of several nationally recognised testing and diagnostic facilities integrated into one unified lab services organisation, offering clients unparalleled access to connectivity, healthcare resources and consultative partnerships.
Date Published: 13/02/2020
Target: Strand Diagnostics
Country: USA
Sector: Healthcare
Type: Corporate acquisition
Status: Closed
Buyer: P4 Diagnostix
Terms of the deal were not disclosed